DC
LXRX icon

Diametric Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Diametric Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
+67,841
New +$98.6K 0.03% 416
2023
Q3 		– Sell
-13,988
Closed -$32K – 389
2023
Q2 		$32K Buy
+13,988
New +$37.1K 0.01% 316

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Diametric Capital's LXRX Position: Q1 2026 in Review

Diametric Capital opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 67,841 shares worth $106K. The stake represents 0.03% of the portfolio and ranks #416 among its holdings. This is a return to the name: Diametric Capital previously reported a position in LXRX as recently as Q2 2023.

Diametric Capital first reported a position in LXRX in Q2 2023 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Diametric Capital held 67,841 shares of Lexicon Pharmaceuticals worth $106K as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Diametric Capital position in Q1 2026.
  • Lexicon Pharmaceuticals made up 0.03% of Diametric Capital's portfolio in Q1 2026, its #416 holding.
  • Diametric Capital first reported a position in Lexicon Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.